Here's another survey that may be of interest to some readers. This one polls attendees of the European Antibody Congress as to what trends they see as most important in the coming months. You can read the very short survey yourself and all the responses but I will highlight two here.
Q. What is the single biggest game changer that has happened in the antibody and next generation technology sector in the last 12 months?
A. The top response is the approval of Adcetris and continued growth of antibody-drug conjugates. With Adcetris and subsequent approval of Kadcyla, this field has kicked into acceptability and there are now 30+ programs in the clinical pipeline.
Q. What is the single biggest game changer likely to be in the antibody and next generation technology sector over the next 12 months?
A. Bispecific antibodies are being developed -- mostly in the cancer field. Only Trion Pharma's Removab is currently approved.
There are more responses to each question above and also several more questions for you to check out below. If you want to see more of these type of surveys, go to the Total Biopharma site.
Posted by Bruce Lehr Aug 14th